Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2020-07-08
Original market date: See footnote 1
2020-07-08
Product name:
TRI-JORDYNA 21
DIN:
02486296
Product Monograph/Veterinary Labelling:
Date:
2020-06-18
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
GLENMARK PHARMACEUTICALS CANADA INC.
1600 Steeles Ave. W., Suite 407
Concord
Ontario
Canada
L4K 4M2
Class:
Human
Dosage form(s):
Tablet
Route(s) of administration:
Oral
Number of active ingredient(s):
6
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
68:12.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
G03AB09 NORGESTIMATE AND ETHINYLESTRADIOL
Active ingredient group (AIG) number:See footnote5
0636783002
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| ETHINYL ESTRADIOL | 0.035 MG |
| ETHINYL ESTRADIOL | 0.035 MG |
| ETHINYL ESTRADIOL | 0.035 MG |
| NORGESTIMATE | 0.18 MG |
| NORGESTIMATE | 0.215 MG |
| NORGESTIMATE | 0.25 MG |